Vanguard Group’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-90,003
Closed -$38K 4189
2018
Q4
$38K Sell
90,003
-284,214
-76% -$177K ﹤0.01% 4093
2018
Q3
$361K Hold
374,217
﹤0.01% 3904
2018
Q2
$909K Buy
374,217
+768
+0.2% +$1.88K ﹤0.01% 3714
2018
Q1
$892K Buy
373,449
+45,959
+14% +$116K ﹤0.01% 3670
2017
Q4
$786K Buy
327,490
+100
+0% +$277 ﹤0.01% 3663
2017
Q3
$1.03M Sell
327,390
-75,033
-19% -$241K ﹤0.01% 3584
2017
Q2
$1.62M Buy
402,423
+56,182
+16% +$245K ﹤0.01% 3448
2017
Q1
$1.28M Buy
346,241
+90,682
+35% +$285K ﹤0.01% 3520
2016
Q4
$496K Buy
255,559
+161,443
+172% +$584K ﹤0.01% 3735
2016
Q3
$585K Sell
94,116
-89,933
-49% -$554K ﹤0.01% 3722
2016
Q2
$824K Buy
184,049
+4,387
+2% +$28.6K ﹤0.01% 3661
2016
Q1
$1.89M Buy
179,662
+651
+0.4% +$12.9K ﹤0.01% 3405
2015
Q4
$5.28M Buy
179,011
+5,026
+3% +$152K ﹤0.01% 2965
2015
Q3
$5.5M Buy
173,985
+82,812
+91% +$3.96M ﹤0.01% 2924
2015
Q2
$5.4M Buy
91,173
+5,497
+6% +$388K ﹤0.01% 2984
2015
Q1
$9.16M Buy
85,676
+16,361
+24% +$1.56M ﹤0.01% 2685
2014
Q4
$6.51M Buy
69,315
+6,645
+11% +$634K ﹤0.01% 2754
2014
Q3
$4.81M Buy
62,670
+11,042
+21% +$870K ﹤0.01% 2844
2014
Q2
$4.64M Buy
51,628
+5,353
+12% +$328K ﹤0.01% 2873
2014
Q1
$2.48M Buy
46,275
+6,800
+17% +$224K ﹤0.01% 3127
2013
Q4
$994K Buy
39,475
+77
+0.2% +$1.83K ﹤0.01% 3418
2013
Q3
$1.08M Buy
39,398
+10,621
+37% +$342K ﹤0.01% 3346
2013
Q2
$1.04M Buy
+28,777
New +$1.08M ﹤0.01% 3302

Vanguard Group's PTX Position: Q1 2019 in Review

Vanguard Group sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 90,003 shares — an estimated $38K sold.

Vanguard Group first reported a position in PTX in Q2 2013 and held it in 23 quarters. The position peaked at $9.16M in Q1 2015. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.

  • Vanguard Group reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
  • Vanguard Group sold 90,003 Pernix Therapeutics Holdings, Inc. shares in Q1 2019, an estimated $38K.
  • Vanguard Group first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2013 and held it in 23 quarters.
  • Vanguard Group's Pernix Therapeutics Holdings, Inc. position peaked at $9.16M in Q1 2015.
  • 1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.

Based on Vanguard Group's 13F filing for Q1 2019, filed 15 May 2019.